GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cancer Genetics Inc (NAS:CGIX) » Definitions » E10

Cancer Genetics (Cancer Genetics) E10 : $-67.78 (As of Dec. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Cancer Genetics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cancer Genetics's adjusted earnings per share data for the three months ended in Dec. 2020 was $-1.230. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-67.78 for the trailing ten years ended in Dec. 2020.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-05), Cancer Genetics's current stock price is $4.61. Cancer Genetics's E10 for the quarter that ended in Dec. 2020 was $-67.78. Cancer Genetics's Shiller PE Ratio of today is .


Cancer Genetics E10 Historical Data

The historical data trend for Cancer Genetics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Genetics E10 Chart

Cancer Genetics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -67.78

Cancer Genetics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -69.79 -68.76 -67.78

Competitive Comparison of Cancer Genetics's E10

For the Biotechnology subindustry, Cancer Genetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cancer Genetics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cancer Genetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cancer Genetics's Shiller PE Ratio falls into.



Cancer Genetics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cancer Genetics's adjusted earnings per share data for the three months ended in Dec. 2020 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=-1.23/109.8968*109.8968
=-1.230

Current CPI (Dec. 2020) = 109.8968.

Cancer Genetics Quarterly Data

per share eps CPI Adj_EPS
201103 -75.806 94.283 -88.360
201106 -52.168 95.235 -60.200
201109 -12.660 95.727 -14.534
201112 -25.418 95.213 -29.338
201203 -22.124 96.783 -25.122
201206 -27.661 96.819 -31.397
201209 -25.209 97.633 -28.376
201212 -37.224 96.871 -42.229
201303 -20.987 98.209 -23.485
201306 -68.701 98.518 -76.636
201309 -18.300 98.790 -20.357
201312 -9.903 98.326 -11.068
201403 -8.100 99.695 -8.929
201406 -14.100 100.560 -15.409
201409 -15.300 100.428 -16.743
201412 -16.500 99.070 -18.303
201503 -13.200 99.621 -14.562
201506 -15.300 100.684 -16.700
201509 -16.800 100.392 -18.391
201512 -14.400 99.792 -15.858
201603 -11.700 100.470 -12.798
201606 -8.400 101.688 -9.078
201609 -6.900 101.861 -7.444
201612 -4.500 101.863 -4.855
201703 -15.300 102.862 -16.346
201706 -4.800 103.349 -5.104
201709 -4.500 104.136 -4.749
201712 -10.800 104.011 -11.411
201803 -4.800 105.290 -5.010
201806 -3.900 106.317 -4.031
201809 -9.247 106.507 -9.541
201812 -4.223 105.998 -4.378
201903 -2.830 107.251 -2.900
201906 -1.980 108.070 -2.013
201909 0.980 108.329 0.994
201912 -0.010 108.420 -0.010
202003 -0.560 108.902 -0.565
202006 -0.790 108.767 -0.798
202009 -0.580 109.815 -0.580
202012 -1.230 109.897 -1.230

Add all the adjusted EPS together and divide 10 will get our e10.


Cancer Genetics  (NAS:CGIX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cancer Genetics E10 Related Terms

Thank you for viewing the detailed overview of Cancer Genetics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Cancer Genetics (Cancer Genetics) Business Description

Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Meadows Office Complex, Rutherford, NJ, USA, 07070
Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The company is focused on precision and translational medicine to drive drug discovery and novel therapies. Its subsidiary, vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. VivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.
Executives
Ralf Brandt officer: President, Discovery Services 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Glenn Miles officer: Chief Financial Officer C/O CANCER GENETICS INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Franklyn G Prendergast director
Chaganti Raju S.k. director 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Edmund Cannon director 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Geoffrey E. Harris director 8 HARTLEY FARMS ROAD, MORRISTOWN NJ 07960
Howard Mcleod director 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
John Pappajohn director 1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
John A Roberts officer: Chief Executive Officer C/O CANCER GENETICS, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
William Lansing Finger officer: EVP Precision Medicine 201 ROUTE 17N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Brian Mccartney officer: Chief Commercial Officer C/O CANCER GENETICS, INC., 201 ROUTE 17 N, 2ND FLOOR, RUTHERFORD NJ 07070
Rita Shaknovich officer: Chief Medical Officer C/O CANCER GENETICS, INC. 201 ROUTE 17N, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas F Widmann director 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael J. Welsh director UNIV. OF IOWA CARVER COLLEGE OF MEDICINE, DEPT. OF INTERNAL MEDICINE, 500 EMRB, IOWA CITY IA 52242
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070